By Chris Wack

 

Mirum Pharmaceuticals Inc. said it has submitted a marketing authorization application for the treatment of cholestatic liver disease in patients with Alagille syndrome to the European Medicines Agency.

In conjunction with the ALGS submission, Mirum's marketing authorization application for progressive familial intrahepatic cholestasis type 2 was withdrawn with plans to re-submit after availability of results from its Phase 3 study in a broader set of PFIC sub-types and with higher doses of maralixibat.

In the U.S., the Food and Drug Administration has accepted Mirum's new drug application for maralixibat for the treatment of cholestatic pruritus in patients with ALGS and the company is preparing for a potential launch following the PDUFA date of Sept. 29, if approved by the FDA.

Mirum shares were up 5% to $19 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

September 13, 2021 07:37 ET (11:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Mirum Pharmaceuticals Charts.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Mirum Pharmaceuticals Charts.